186 related articles for article (PubMed ID: 15642745)
1. The Pim kinases control rapamycin-resistant T cell survival and activation.
Fox CJ; Hammerman PS; Thompson CB
J Exp Med; 2005 Jan; 201(2):259-66. PubMed ID: 15642745
[TBL] [Abstract][Full Text] [Related]
2. The Pim kinase pathway contributes to survival signaling in primed CD8+ T cells upon CD27 costimulation.
Peperzak V; Veraar EA; Keller AM; Xiao Y; Borst J
J Immunol; 2010 Dec; 185(11):6670-8. PubMed ID: 21048108
[TBL] [Abstract][Full Text] [Related]
3. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.
Fox CJ; Hammerman PS; Cinalli RM; Master SR; Chodosh LA; Thompson CB
Genes Dev; 2003 Aug; 17(15):1841-54. PubMed ID: 12869584
[TBL] [Abstract][Full Text] [Related]
4. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
5. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis.
Wang Z; Bhattacharya N; Weaver M; Petersen K; Meyer M; Gapter L; Magnuson NS
J Vet Sci; 2001 Dec; 2(3):167-79. PubMed ID: 12441685
[TBL] [Abstract][Full Text] [Related]
6. Anti-Pim-1 mAb inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survival.
Li J; Loveland BE; Xing PX
Cell Immunol; 2011; 272(1):87-93. PubMed ID: 21974958
[TBL] [Abstract][Full Text] [Related]
7. Expression of the pim-1 protooncogene: differential inducibility between alpha/beta- and gamma/delta-T cells and B cells.
Wingett D; Stone D; Davis WC; Magnuson NS
Cell Immunol; 1995 Apr; 162(1):123-30. PubMed ID: 7704900
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates.
Kim JS; Lee JI; Shin JY; Kim SY; Shin JS; Lim JH; Cho HS; Yoon IH; Kim KH; Kim SJ; Park CG
Transplantation; 2009 Dec; 88(12):1349-59. PubMed ID: 20029331
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation.
Hammerman PS; Fox CJ; Cinalli RM; Xu A; Wagner JD; Lindsten T; Thompson CB
Cancer Res; 2004 Nov; 64(22):8341-8. PubMed ID: 15548703
[TBL] [Abstract][Full Text] [Related]
10. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors.
Mikkers H; Nawijn M; Allen J; Brouwers C; Verhoeven E; Jonkers J; Berns A
Mol Cell Biol; 2004 Jul; 24(13):6104-15. PubMed ID: 15199164
[TBL] [Abstract][Full Text] [Related]
11. The serine/threonine kinase Pim-1.
Bachmann M; Möröy T
Int J Biochem Cell Biol; 2005 Apr; 37(4):726-30. PubMed ID: 15694833
[TBL] [Abstract][Full Text] [Related]
12. Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation.
Walpen T; Kalus I; Schwaller J; Peier MA; Battegay EJ; Humar R
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):24-30. PubMed ID: 23131564
[TBL] [Abstract][Full Text] [Related]
13. L-leucine availability regulates phosphatidylinositol 3-kinase, p70 S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway in the L-leucine-induced up-regulation of system A amino acid transport.
Peyrollier K; Hajduch E; Blair AS; Hyde R; Hundal HS
Biochem J; 2000 Sep; 350 Pt 2(Pt 2):361-8. PubMed ID: 10947949
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival.
Gonzalez J; Harris T; Childs G; Prystowsky MB
Blood Cells Mol Dis; 2001; 27(3):572-85. PubMed ID: 11355896
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation.
Nomura M; He Z; Koyama I; Ma WY; Miyamoto K; Dong Z
Mol Carcinog; 2003 Sep; 38(1):25-32. PubMed ID: 12949840
[TBL] [Abstract][Full Text] [Related]
16. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival.
Woodland RT; Fox CJ; Schmidt MR; Hammerman PS; Opferman JT; Korsmeyer SJ; Hilbert DM; Thompson CB
Blood; 2008 Jan; 111(2):750-60. PubMed ID: 17942753
[TBL] [Abstract][Full Text] [Related]
17. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site.
Aho TL; Sandholm J; Peltola KJ; Mankonen HP; Lilly M; Koskinen PJ
FEBS Lett; 2004 Jul; 571(1-3):43-9. PubMed ID: 15280015
[TBL] [Abstract][Full Text] [Related]
18. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin.
Basu S; Golovina T; Mikheeva T; June CH; Riley JL
J Immunol; 2008 May; 180(9):5794-8. PubMed ID: 18424697
[TBL] [Abstract][Full Text] [Related]
19. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
Szydłowski M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Derezińska E; Hoser G; Wasilewska D; Szymańska-Giemza O; Jabłońska E; Białopiotrowicz E; Sewastianik T; Polak A; Czardybon W; Gałęzowski M; Windak R; Zaucha JM; Warzocha K; Brzózka K; Juszczyński P
Blood; 2017 Sep; 130(12):1418-1429. PubMed ID: 28698206
[TBL] [Abstract][Full Text] [Related]
20. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival.
Hammerman PS; Fox CJ; Birnbaum MJ; Thompson CB
Blood; 2005 Jun; 105(11):4477-83. PubMed ID: 15705789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
